Endo Investors

Cecelia Health, Inc. is a technology-enabled company based in New York that specializes in remote telehealth support and chronic disease management, particularly focusing on diabetes care. Founded in 2006 and formerly known as Fit4D, the company provides clinical support and coaching services for individuals with Type 1 and Type 2 diabetes, as well as those managing other chronic conditions such as obesity and cardiovascular disease. Cecelia Health combines expert clinical coaching with digital health tools to enhance patient adherence to medications and wellness programs. The company's approach emphasizes personalized coaching and patient engagement, utilizing both virtual care and telehealth solutions to improve health outcomes. Through its services, Cecelia Health aims to transform the lives of its patients by fostering better self-management and promoting positive behavior changes.

Capillary Biomedical, Inc. is a medical device company based in Irvine, California, established in 2014 as a spin-out from the Artificial Pancreas Center at the Sidney Kimmel Medical College. The company focuses on developing innovative technologies for diabetes management, aiming to simplify the processes of glucose monitoring and insulin delivery. Their signature product features a kink-proof, flexible, multiport cannula designed to enhance the reliability and comfort of insulin delivery. This user-friendly device allows for simple one-handed insertion, enabling diabetes patients to better manage their blood glucose levels and alleviating some of the burdens associated with diabetes on both individuals and the healthcare system.

Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.

Mellitus Health is a healthcare technology company based in Los Angeles, California, founded in 2013. It specializes in developing cloud-based software for precision insulin dosing recommendations. The company's flagship product, Insulin Insights, provides clinicians with tailored insulin dosage recommendations to optimize treatment regimens. By offering patient-specific adjustments, Mellitus Health aims to reduce blood glucose levels, complications, and overall healthcare costs associated with diabetes management.

Biolinq Inc. is a San Diego-based company specializing in the development of innovative skin-applied electronic sensors designed to analyze body fluids and deliver health insights. Founded in 2012, Biolinq focuses on creating a digital health platform that facilitates biomonitoring solutions. Its flagship product is a minimally invasive electrochemical biosensor that continuously monitors various biomarkers in interstitial fluid, including glucose, ketones, and lactate. This technology enables diabetic patients to track their blood glucose levels without the discomfort associated with traditional monitoring methods. By providing actionable health information and insights, Biolinq aims to enhance metabolic health and improve the quality of life for individuals managing diabetes.

ILiAD Biotechnologies, LLC is a clinical-stage biotechnology company based in Weston, Florida, founded in 2012. The company specializes in the development and manufacture of vaccines aimed at preventing and treating diseases caused by Bordetella pertussis, the bacterium responsible for whooping cough. ILiAD's lead product, BPZE1, is a live-attenuated pertussis vaccine that has successfully completed Phase 1 human clinical trials. This innovative vaccine is designed to stimulate the immune system to produce protective antibodies, enabling patients to recover from whooping cough and reduce the incidence of this serious disease.